Últimas investigaciones científicas sobre cáncer colorrectal
Copia esta URL y pégala en tu lector RSS favorito (Feedly, Inoreader, etc.)
https://crcwarriors.org/api/scientific-news.php?action=rss
Investigator-initiated studies that include information collected by patients are rising, but limited data is available on patient and investigator experience in this setting. The I-CARE cohort included patients with inflammatory bowel disease (IBD) monthly collecting clinical information in 15 coun...
Colorectal cancer (CRC) is one of the leading causes of cancer-related mortality worldwide, largely due to therapeutic resistance and inefficient drug delivery. Here, we report the development of a targeted and biocompatible siRNA delivery platform designed to silence RNA methyltransferase NSUN2, a ...
Colorectal carcinoma (CRC) is the most prevalent malignancy of the gastrointestinal tract and remains a leading cause of cancer-related illness and death worldwide. Recently, new treatment strategies have emerged with the identification of important biomarkers in CRC. As the emphasis on precision me...
Immune checkpoint inhibitors (ICIs) have fundamentally transformed the treatment landscape for localized colorectal cancer (CRC), particularly for the mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) subgroups. This review evaluates the current clinical evidence and evolvi...
Immune checkpoint inhibitors (ICIs) have shown limited efficacy in patients with microsatellite-stable/DNA mismatch repair-proficient (MSS/pMMR) metastatic colorectal cancer (CRC). Based on data suggesting antitumor synergy between ICIs and MEK inhibitors, the phase II CheckMate 142 trial evaluated ...
Ovarian mucinous carcinoma (OMC) is a rare subtype of ovarian cancer characterized by frequent KRAS mutations and a poor response to platinum- and taxane-based chemotherapy, underscoring the need for novel therapeutic strategies. MRTX1133, a recently developed non-covalent and selective KRAS (G12D) ...
Resistance to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAb) is common in metastatic colorectal cancer (mCRC) and reliable predictive biomarkers remain lacking. The identification of new predictive biomarkers is therefore necessary to assess the efficacy of anti-EGFR mAb, i...
Alterations in the mitogen-activated protein kinase (MAPK) pathway play a central role in colorectal cancer (CRC) tumor biology, therapeutic response, and resistance. RAS oncogenic mutations are present in up to 35% of CRC; they represent constitutively active molecular switches that impair GTP hydr...
Antibody-drug conjugates (ADCs), bispecific T-cell engagers (TCEs), and chimeric antigen receptor (CAR)-T cells require truly tumor-restricted surface antigens to minimize on-target/off-tumor toxicity. To identify such antigens, we interrogated two complementary RNA-seq resources: (i) the Genotype-T...
Biomarkers predicting response to trifluridine/tipiracil (FTD/TPI) with or without bevacizumab (BEV) in refractory metastatic colorectal cancer (mCRC) remain unclear. We identified candidate biomarkers in preclinical models and evaluated their clinical relevance. Candidate biomarkers were identified...
Reliable and minimally invasive biomarkers are needed for early detection, prognosis, and monitoring of colon cancer (CC). The aim of our study was to evaluate the role of systemic nitric oxide (NO) in inflammation and tumor progression and its diagnostic and prognostic value in CC. This prospective...
Photothermal therapy (PTT) alone is insufficient for the complete elimination of malignant cells, which may lead to recurrence and metastasis. Thus, PTT is usually used in combination with immunomodulatory therapy. Herein, hybrid cell membrane biomimetic nanoparticle was developed by fusing a Raw 26...
Colorectal liver metastases (CRLM) are a leading cause of mortality in patients with colorectal cancer. While surgical resection is the standard curative option, most patients are ineligible. Consequently, cryoablation (CA) has emerged as a potential alternative. This review aims to summarise the te...
Colorectal cancer is the second leading cause of cancer-related mortality worldwide, posing a substantial burden on healthcare systems. Identifying DNA mismatch repair deficiency (dMMR) is critical for guiding treatment, yet conventional methods rely on labor-intensive DNA analysis. While deep-learn...
Cancer‑associated fibroblasts (CAFs) play critical roles in the tumor microenvironment (TME); however, their characteristics under hypoxic conditions remain incompletely understood. The aim of the present study was to investigate the properties of hypoxic CAFs and identify their regulatory factors...
Colorectal cancer (CRC) is a malignancy with high global incidence and mortality rates, necessitating innovative approaches to decipher its biological characteristics and clinical behaviors. The integration of single-cell sequencing and spatial transcriptomics has emerged as a revolutionary tool in ...
TNMplot.com, a web-based platform integrating RNA-Seq and gene-chip data from 56,938 samples, enables differential gene expression analysis across normal, primary tumour and metastatic tissues, facilitating large-scale transcriptomic profiling across 22 tumour types. We introduced an updated version...
Formyl Peptide Receptor 1 (FPR1), a Class A G protein-coupled receptor (GPCR), is a context-dependent regulator at the interface of gastrointestinal inflammation and cancer. Recent structural insights have revealed its functional diversity. FPR1 responds to diverse exogenous and endogenous ligands, ...
The 6th Edition of the WHO Classification of Digestive System Tumours represents a significant update to the 5th edition. It integrates pathological, new molecular, and clinical insights to refine the taxonomy of digestive system neoplasms. The revised classification continues to emphasise standardi...
Patients with rectal cancer who have a complete clinical response (cCR) to neoadjuvant chemo/radiotherapy (nCRT) may opt for organ preservation and watch and wait (W&W). This consists of an intense surveillance program including serial endoscopies, pelvic magnetic resonance imaging (MRI), carcinoemb...
The BRAF V600 mutation confers a poor prognosis in metastatic colorectal cancer (mCRC). Mosperafenib is a novel, paradox-breaking BRAF inhibitor (BRAFi). In this analysis of a phase 1 study (ISRCTN13713551), we evaluated circulating tumor DNA (ctDNA) as a prognostic and predictive biomarker for mosp...
Troxerutin (TXN), a hydroxyethylated derivative of rutin, has gained increasing attention as a bioactive flavonoid with multifaceted anticancer properties. Its pharmacological effects, particularly antioxidant, anti-inflammatory, and anti-angiogenic activities, play a crucial role in modulating canc...
Tyrosyl-DNA phosphodiesterase 1 (TDP1) is a potential radiotherapeutic target for cancer treatment. Herein, two series of analogues, benzophenanthridinone derivatives and benzophenanthridine derivatives, were designed and synthesized based on the reported TDP1 inhibitor NTD119B showing strong radios...
In neoadjuvant immunotherapy, radiological assessment of pathological complete response (pCR) is frequently inaccurate, and atypical response patterns are occasionally observed. This study aims to investigate the diagnostic performance of new qualitative morphological changes for predicting pCR and ...
Immunotherapy has transformed the management of some solid tumor types, but its impact has been limited to the subset of cancer patients who have "hot" or immunogenic tumors. Num2erous studies are based on strategies for turning "cold," or immune-unresponsive, tumors into a "hot" state. The gut micr...
Purpose:UGT1A1 gene polymorphisms are established risk factors for irinotecan (CPT-11)-induced toxicity. The FOLFIRI-3 regimen, incorporating split-dose CPT-11 administration on Days 1 and 3, was developed to improve safety and efficacy. This study evaluated the clinical outcomes of FOLFIRI-3 strati...
The introduction of biosimilars can lead to substantial price reductions which can alter cost-effectiveness conclusions in health technology assessments. This study, undertaken for the National Institute for Health and Care Excellence (NICE), aimed to pilot a test-and-learn approach for biosimilars ...
Chemotherapy with spatiotemporal precision and noninvasiveness offers a new treatment strategy for colorectal cancer. However, this therapy still has shortcomings in how chemotherapeutic drugs are visualized and their antitumor effects. To improve the therapeutic efficacy, we have fabricated a facil...
METTL3 is a pivotal N6-methyladenosine (m⁶A) regulator that is linked to a worse prognosis of colorectal cancer (CRC). However, METTL3's oncogenic molecular networks in CRC remain unclear. This study aims to establish a co-expression network of METTL3 and identify novel diagnostic and therapeutic ...
Colorectal cancer (CRC) remains a major global health burden and a leading cause of cancer-related morbidity and mortality. Current blood-based biomarkers lack sufficient sensitivity and specificity, particularly for early detection. In this context, circulating immune-cell transcriptomic profiling ...
Synchronous colorectal cancers (SCRCs) with discordant mismatch repair (MMR) status present unique clinical and therapeutic challenges. This case report describes a rare instance of synchronous ascending colon and rectal adenocarcinomas arising from distinct tumorigenic pathways (Lynch-like syndrome...
T-cell exhaustion in the tumor microenvironment undermines anti-tumor immunity and limits immunotherapy efficacy. Further defining the metabolic triggers of this dysfunctional state could provide therapeutic targets for circumventing immunosuppression. Here we identified soluble uric acid (UA)-an ab...
Prognosis of metastatic oesogastric adenocarcinoma (mOGC) beyond second‑line therapy remains poor. Trifluridine/tipiracil monotherapy is recommended in later lines but provides limited survival benefits. Anti‑angiogenic drugs have demonstrated significant efficacy in mOGC. Fruquintinib is a sele...
T-cell responses influence recurrence and survival in colorectal cancer. T-cell subset distributions vary by molecular phenotype and anatomic location, shaping cytotoxic or immune-cold tumor immune microenvironments. However, the T-cell contexture and their spatial proximities within preinvasive les...
Colorectal cancer liver metastasis remains a significant challenge, with systemic inflammation and liver fibrosis emerging as key prognostic factors. This study evaluates the individual and combined prognostic significance of the Systemic Inflammation Index and Fibrosis-4 index in CRLM patients unde...
The most frequent malignancies affecting women are cervical, breast, ovarian, and uterine cancers, which account for the majority of cancer-related deaths among women in both developed and developing nations. These cancers exhibit high aggressiveness due to their invasive and metastatic potential. C...
The HGF/SF (hepatocyte growth factor/scatter factor) receptor tyrosine kinase MET is overexpressed and/or activated in many tumors, providing therapeutic targets for antibody-drug conjugates and tyrosine kinase inhibitors. Reliable measurement of activated MET is fundamental for pharmacodynamic asse...
ERBB2 aberrations are established oncogenic drivers with validated therapeutic relevance in breast cancer and emerging indications across solid tumors. In gastrointestinal malignancies, the prevalence, molecular contexts, and therapeutic implications of ERBB2 alterations remain incompletely defined,...
PDAC has high mortality rates and limited treatment options. KRAS mutations are present in > 90% of patients with PDAC, causing constitutive activation of the MAPK pathway. Preclinical studies demonstrated synergistic antitumor activity in in vivo and in vitro KRAS-mutant PDAC models by combining ...
Colorectal cancer (CRC), the third most commonly diagnosed cancer worldwide, presents a growing public health concern, with 20% of new diagnoses involving de novo metastatic disease and up to 80% of these patients presenting with unresectable metastatic lesions. Microsatellite instability-high (MSI-...
This study provides a molecular characterization of precancerous colorectal lesions in Lynch syndrome (LS) carriers to assess the preventive potential of Nous-209 immunotherapy against colorectal cancer development. A total of 50 adenomas and 12 advanced adenomas (AA) were collected from 26 LS carri...
Xiao-Chai-Hu-Tang (XCHT) is a classical multi-herb formula widely used for gastrointestinal symptoms and peptic ulcers. Our previous preclinical studies have shown that XCHT attenuated irinotecan-induced severe delayed-onset diarrhea (SDOD). However, the clinical safety of XCHT combined with irinote...
5-Fluorouracil (5-FU) is a widely utilized antimetabolite in colorectal cancer chemotherapy, primarily exerting its cytotoxic effects by irreversibly inhibiting thymidylate synthase (TS). This inhibition leads to a reduction in deoxythymidine monophosphate (dTMP), which disrupts DNA synthesis and re...
Treatment with immune checkpoint inhibitors in colorectal cancer (CRC) has largely benefited patients with microsatellite instability-high (MSI-H) and not the larger proportion of patient with microsatellite-stable (MSS) tumors. This clinical dichotomy has fueled the view that high mutational burden...
Commensal bacteria play a crucial role in modulating human immune responses in the intestine. Under homeostatic conditions, the gut microbiota is tightly regulated by interactions with the mucosal immune system. However, colorectal cancer (CRC) is characterized by an imbalance in bacterial compositi...
Colorectal cancer (CRC) exhibits substantial prognostic heterogeneity, and immune checkpoint inhibitors benefit only approximately 10%-15% of patients with mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) status. Therefore, there is an urgent need for risk stratification tools ...
One of the biggest causes of cancer-related mortality worldwide is still colon adenocarcinoma (COAD). Therefore, it is essential to investigate new therapy strategies. This study presents a multi-scale, hypothesis-generating framework that integrates network pharmacology with multi-omics data and qu...
Analyzing colorectal cancer (CRC) tumor heterogeneity reveals key clues for identifying new therapeutic targets. This study systematically investigates cellular heterogeneity and potential biomarkers in CRC through the integration of single-cell and bulk transcriptomic data. By integrating single-ce...
The precise identification of cancer driver mutations is essential for precision oncology; however, it remains a significant challenge because of the overwhelming presence of passenger mutations and the complexity of mutational processes. In this study, we introduce ResMLP-GL, a signature-aware resi...
Immunotherapy has improved outcomes in metastatic colorectal cancer (mCRC), but benefits remain largely restricted to the minority with specific biomarkers like microsatellite instability-high (MSI-H). This study aims to develop and validate a revised tumor burden score (rTBS) as a prognostic model ...